亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫(yī)藥中間體

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > abaloparatide阿巴洛肽247062-33-5
abaloparatide阿巴洛肽247062-33-5
單價 50.00 / g對比
銷量 暫無
發(fā)貨 四川成都市付款后3天內(nèi)
庫存 1000g起訂0.05g
品牌 成都云希
外觀 白色粉末
cas 247062-33-5
分子式 C174H299N56O49
過期 長期有效
更新 2021-07-07 11:37
 
詳細(xì)信息

Name: abaloparatide

CAS No. :247062-33-5

Sequence: H-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2

     Molecular formula: C174H299N56O49

Molecular weight :  3959.65

Purity:  >98.0%

Source:  synthetic

MSDS and COA: available

Details: Abaloparatide is an analog of human pTHrP (1-34). It is a potent and selective activator of the parathyroid hormone receptor (PTH1R) signaling pathway and can stimulate bone formation with less of the ac*panying bone resorption and hypercalcemic effects that can occur with pTH (1-34). Abaloparatide can be used in research for osteoporosis in postmenopausal women who have a high risk of bone fracture.

©2025 成都云希化工有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:41600  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |